Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular characterization of high-level-cholera-toxin-producing El Tor variant Vibrio cholerae strains in the Zanzibar Archipelago of Tanzania.
Naha A, Chowdhury G, Ghosh-Banerjee J, Senoh M, Takahashi T, Ley B, Thriemer K, Deen J, Seidlein LV, Ali SM, Khatib A, Ramamurthy T, Nandy RK, Nair GB, Takeda Y, Mukhopadhyay AK. Naha A, et al. Among authors: thriemer k. J Clin Microbiol. 2013 Mar;51(3):1040-5. doi: 10.1128/JCM.03162-12. Epub 2013 Jan 16. J Clin Microbiol. 2013. PMID: 23325815 Free PMC article.
Adapting international clinical trials during COVID-19 and beyond.
Thriemer K, Degaga TS, Alam MS, Adhikari B, Tripura R, Hossain MS, Christian M, Ghanchi NK, Mnjala H, Weston S, Ley B, Rumaseb A, Tadesse D, Teferi T, Yilma D, Lee G, Unger H, Sutanto I, Pasaribu AP, Ghimire P, Beg MA, Price RN. Thriemer K, et al. Clin Trials. 2023 Jun;20(3):237-241. doi: 10.1177/17407745231154215. Epub 2023 Feb 11. Clin Trials. 2023. PMID: 36772825 Free PMC article.
The heterogeneity of symptom reporting across study sites: a secondary analysis of a randomised placebo-controlled multicentre antimalarial trial.
Thriemer K, Commons RJ, Rajasekhar M, Degaga TS, Chand K, Chau NH, Assefa A, Naddim MN, Pasaribu AP, Rahim AG, Sutanto I, Hien TT, Hailu A, Hasanzai MA, Ekawati LL, Woyessa A, Teferi T, Waithira N, Taylor WRJ, Ley B, Dondorp A, Baird JK, White NJ, Day NP, Price RN, Simpson JA, von Seidlein L. Thriemer K, et al. BMC Med Res Methodol. 2023 Sep 4;23(1):198. doi: 10.1186/s12874-023-02022-3. BMC Med Res Methodol. 2023. PMID: 37667204 Free PMC article. Clinical Trial.
Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis.
Rajasekhar M, Simpson JA, Ley B, Edler P, Chu CS, Abreha T, Awab GR, Baird JK, Bancone G, Barber BE, Grigg MJ, Hwang J, Karunajeewa H, Lacerda MVG, Ladeia-Andrade S, Llanos-Cuentas A, Pukrittayakamee S, Rijal KR, Saravu K, Sutanto I, Taylor WRJ, Thriemer K, Watson JA, Guerin PJ, White NJ, Price RN, Commons RJ; WorldWide Antimalarial Resistance Network (WWARN) Vivax Primaquine Dosing Efficacy, Tolerability and Safety Study Group. Rajasekhar M, et al. Among authors: thriemer k. Lancet Infect Dis. 2024 Feb;24(2):184-195. doi: 10.1016/S1473-3099(23)00431-0. Epub 2023 Sep 22. Lancet Infect Dis. 2024. PMID: 37748497 Free PMC article.
Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis.
Mehdipour P, Rajasekhar M, Dini S, Zaloumis S, Abreha T, Adam I, Awab GR, Baird JK, Brasil LW, Chu CS, Cui L, Daher A, do Socorro M Gomes M, Gonzalez-Ceron L, Hwang J, Karunajeewa H, Lacerda MVG, Ladeia-Andrade S, Leslie T, Ley B, Lidia K, Llanos-Cuentas A, Longley RJ, Monteiro WM, Pereira DB, Rijal KR, Saravu K, Sutanto I, Taylor WRJ, Thanh PV, Thriemer K, Vieira JLF, White NJ, Zuluaga-Idarraga LM, Guerin PJ, Price RN, Simpson JA, Commons RJ; WWARN Vivax Adherence Study Group. Mehdipour P, et al. Among authors: thriemer k. Malar J. 2023 Oct 10;22(1):306. doi: 10.1186/s12936-023-04725-w. Malar J. 2023. PMID: 37817240 Free PMC article.
111 results